Our leading subject matter experts share their insightful analysis and points of view to help you stay abreast of industry trends
For years, immunology has ranked as one of the top therapeutic areas by value, with year-over-year growth driven by blockbuster biologics for conditions like rheumatoid arthritis (RA), psoriasis, and inflammatory…
Pharma manufacturers invest significant time and money developing resources for payers, from budget impact models to PIE packages and NCCN summaries. But are those resources hitting the mark?
New Q1…
Launching a new therapy is one of the most consequential moments in a pharmaceutical brand’s lifecycle. As we’ve said before, you only launch once! The difference between brands that achieve…
Cell and gene therapies are no longer reserved only for ultra-rare diseases. In many therapeutic areas (TAs), advances in viral vector delivery, gene editing technologies, and cell-based medicine are enabling…
For many manufacturers, the period between FDA submission and the PDUFA date feels deceptively quiet. Clinical work is largely complete, pricing assumptions have already been modeled, and commercial teams are…
Portfolio contracting is quietly rewriting the rules of pharmaceutical market access. What began as a way to bundle a handful of related products has evolved into a defining access strategy…
Copay accumulator and maximizer programs are now firmly embedded in the commercial market, and their influence on patient access and manufacturer strategy is becoming impossible to overlook. In the first…
As payers continue to refine their cost-containment strategies, copay accumulator and copay maximizer programs have quietly become standard tools in their playbook. Despite recent legislation, the majority of payers are…
Our latest research at Norstella strongly suggests that a highly dynamic market access situation in the U.S. is feeding back into upstream decisions around R&D strategy. We explored this topic…
Urinary tract infections (UTIs) rank as the most common bacterial infection for women worldwide. Between 50-60% of adult women experience at least one UTI in their lifetime, and approximately 25%…
